Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2023-04-28 Proxy Solicitation & In…
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes voting instructions, details about the annual meeting, election of directors, advisory votes on executive compensation, and ratification of auditors. The presence of proxy materials and voting items indicates this is related to soliciting shareholder votes and providing information for the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is 4226 characters, which is consistent with a proxy statement or related materials rather than a full annual report or other filings. Therefore, the correct classification is PSI.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, related to the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, board of directors, executive compensation, corporate governance, and other shareholder meeting materials. The document is not a report of financial results, audit, or earnings, but rather materials sent to shareholders to provide information and solicit votes for the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2023-04-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.